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ABSTRACT
Objectives To assess the performance of WHO’s
“Guidelines for care at the first-referral level in developing
countries” in an area of intense malaria transmission and
identify bacterial infections in children with and without
malaria.
Design Prospective study.
Setting District hospital in Muheza, northeast Tanzania.
ParticipantsChildren aged 2months to 13 years admitted
to hospital for febrile illness.
Main outcome measures Sensitivity and specificity of
WHO guidelines in diagnosing invasive bacterial disease;
susceptibility of isolated organisms to recommended
antimicrobials.
Results Over one year, 3639 children were enrolled and
184 (5.1%) died; 2195 (60.3%) were blood slide positive
for Plasmodium falciparum, 341 (9.4%) had invasive
bacterial disease, and 142 (3.9%) were seropositive for
HIV. The prevalence of invasive bacterial disease was
lower in slide positive children (100/2195, 4.6%) than in
slide negative children (241/1444, 16.7%). Non-typhi
Salmonella was the most frequently isolated organism
(52/100 (52%) of organisms in slide positive children and
108/241 (45%) in slide negative children). Mortality
among children with invasive bacterial disease was
significantly higher (58/341, 17%) than in children
without invasive bacterial disease (126/3298, 3.8%)
(P<0.001), and this was true regardless of the presence of
P falciparum parasitaemia. The sensitivity and specificity
of WHO criteria in identifying invasive bacterial disease in
slide positive children were 60.0% (95% confidence
interval 58.0% to 62.1%) and 53.5% (51.4% to 55.6%),
compared with 70.5% (68.2% to 72.9%) and 48.1%
(45.6% to 50.7%) in slide negative children. In children
with WHO criteria for invasive bacterial disease, only 99/
211(47%) of isolated organisms were susceptible to the
first recommended antimicrobial agent.
Conclusions In an area exposed to high transmission of
malaria, current WHO guidelines failed to identify almost
a third of children with invasive bacterial disease, and
more than half of the organisms isolated were not
susceptible to currently recommended antimicrobials.
Improved diagnosis and treatment of invasive bacterial
disease are needed to reduce childhood mortality.
INTRODUCTION
Acute febrile illness is the most common cause of hos-
pital admission and death in African children.1 The
large majority of these illnesses are due to malaria or
invasive bacterial disease, but differentiating between
these causes is often difficult and can result in missed
diagnoses and inappropriate treatment.2-7 Although
Plasmodium parasitaemia can be confirmed or
excluded by microscopy or rapid diagnostic tests, the
diagnosis of invasive bacterial disease is more proble-
matic as blood culture is rarely available and is never in
time to guide crucial first treatment decisions. Clini-
cians therefore often have to rely on theWorld Health
Organization’smanual “Management of the childwith
severe infection or severe malnutrition: guidelines for
care at first-referral level in developing countries”
(WHO criteria) to guide the presumptive use of anti
microbials.8
The use of the WHO criteria in an area of moderate
transmission of malaria has been shown to identify a
high proportion of fatalities due to invasive bacterial
disease among children admitted to hospital.9 How-
ever, the criteria have not so far been systematically
assessed in an area of intense transmission of Plasmo-
dium falciparum where infection with Gram negative
organisms, especially non-typhi Salmonella, is rela-
tively common and has been associated with severe
anaemia, HIV infection, and non-specific clinical fea-
tures that are not included in theWHOcriteria for anti-
microbial treatment.3 5 10-14 In these areas, which
include much of rural Africa, clinicians remain uncer-
tain as to which patients to treat and which anti-
microbial to use.
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We report here the results of a one year prospective
study of febrile illness in children admitted to a Tanza-
nian district hospital serving a population exposed to
intense P falciparum transmission to assess the ability of
the WHO criteria to guide appropriate treatment for
invasive bacterial disease.
METHODS
Study site
This was a one year observational study in Teule Hos-
pital, Muheza, northeast Tanzania, a district hospital
serving a rural population of approximately 277 000
people with a mortality in children under 5 of 165 per
1000 (Tanzanian census 2002). Transmission of P falci-
parum is intense (50-700 infected bites/person/year)
and perennial, with two seasonal peaks.15 The commu-
nity prevalence of P falciparum in children aged
2-5 years in the study area was recorded as 88.2% in
2002.15 At the time of the study, routine immunisation
did not include vaccination against either Haemophilus
influenzae or Streptococcus pneumoniae. HIV seropreva-
lence among women attending antenatal clinics was
7.2% in 2007.16 In 2002 only 5% of paediatric admis-
sions were referred for admission from a primary care
facility; the remainer were brought directly to the hos-
pital outpatients department by a parent or caregiver.
Eligibility and enrolment
Consecutive children admitted during the day were
given emergency treatment if needed, and then all chil-
dren were screened for eligibility. Eligible children
were aged 2 months to 13 years with a current fever
or history of fever within the previous 48 hours. We
excluded children with an obvious non-infectious
cause for admission such as trauma, surgery, or
known malignancy. Children were enrolled over five
consecutive days each week. To include children pre-
senting outside normal working hours, we recruited
children from Monday to Friday for the first seven
months and from Wednesday to Sunday for the next
five months. The caregiver of each child in the study
gave written informed consent, and pre-test counsel-
ling was provided before HIV testing.
Clinical data collection
After consent procedures, clinical officers (a grade of
non-physician clinician in Tanzania) assessed children
by using a standard medical history and examination
based on the WHO criteria (table 1). 8 17 Two study
physicians (BN and GM) supervised the collection of
clinical data throughout the study. Case management
was consistentwithWHOguidelines,with the addition
that all children with severe malaria were treated with
broad spectrum antibiotics consistent with the recom-
mendations of previous studies. 18 Admission out-
comes were recorded at discharge or death.
Blood testing and laboratory procedures
After cleaning of the skin, venous blood was drawn for
culture (2-5 ml), haemoglobin and glucose concentra-
tions (Hemocue, Angelholm, Sweden), serum lactate
(Lactate-Pro, Arkray, Kyoto, Japan), HRP-2 based
rapid diagnostic test for P falciparum (Paracheck,
Orchid Biomedical, Mumbai, India), and a full blood
count (Coulter Act/Dif, Beckman-Coulter). We used
two rapid tests (Capillus HIV-1, HIV-2 Test, Trinity
Biotech, Ireland andDetermineHIV-1/2 Test, Abbott
Laboratories, IL, USA) in all children to test for HIV
antibodies; discordant results were resolved by HIV-1
enzyme linked immunosorbent assay (ELISA) (Viro-
nistika UniForm II Plus-O Test, bioMérieux, NC,
USA).19 Children aged under 18 months with positive
Table 1 | WHO criteria for presumptive antimicrobial treatment in children admitted to hospital
WHO criteria Recommended antimicrobial
Chapter, page of guidelines for
care at first referral level8
Sick young infant—any infant aged <2 months admitted to hospital (not included in this
study)
Ampicillin plus gentamicin IV/IM or penicillin plus
gentamicin IV/IM
6.1, 75
Meningo-encephalopathy—BCS<3 or stiff neck or bulging fontanelle or >2 convulsions in
preceding 24 hours
Chloramphenicol plus ampicillin IV/IM or
chloramphenicol plus penicillin IV/IM
5.2, 62
Malaria with shock*—positive slide for malaria plus shock† or BCS<3 or bulging fontanelle
or >2 convulsions in preceding 24 hours
Chloramphenicol plus penicillin IV/IM 5.1.1, 59†
Very severe pneumonia—cough/difficulty breathing plus multiple convulsions or coma or
lethargy or vomiting everything or inability to drink or cyanosis or severe respiratory
distress‡
Chloramphenicol IV/IM or gentamicin plus penicillin
IV/IM§
3.1.1, 30
Severe pneumonia—cough/difficulty breathing plus lower chest indrawing or nasal flaring
or grunting
Benzyl penicillin IV/IM 3.1.2, 32
Non-severe pneumonia—cough/difficulty breathing plus raised respiratory rate for age Amoxycillin PO or co-trimoxazole PO 3.1.3, 32
Septicaemia—negative slide for malaria plus axillary temperature ≥37.5°C plus inability to
drink/feed or lethargy or >2 convulsions in preceding 24 hours or vomiting everything
Chloramphenicol plus penicillin IV/IM 5.4, 67
Severe acute malnutrition—bilateral oedema or severe wasting or weight for height z-score
<−3
Co-trimoxazole PO or amoxycillin plus gentamicin¶
IM/IV
7.2.5, 84
Where categories were used in analysis, children were assigned to one diagnostic category with priority to those higher in list.
BCS=Blantyre coma score; IM=intramuscular; IV=intravenous; PO=oral.
*“Malaria with shock or signs of meningitis” defined in WHO guidelines8; however, children with malaria and signs of meningitis will already be included in category above.
†Shock defined as capillary refill >3 seconds or cool peripheries or systolic blood pressure <50 mm Hg (WHO Pocket Book of Hospital Care for Children 6.2.1, 142).
‡Defined as oxygen saturation <90% or respiratory rate ≥70 breaths/minute.
§Recommended if chloramphenicol is not available.
¶Recommended if hypoglycaemia or hypothermia present or if child seems lethargic or “sickly.”
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results were tested for HIV-1 RNA (Abbott Real-Time
m2000 System, Abbott Molecular, IL, USA).
Giemsa-stained blood slides were prepared from
venous blood and independently double read; discor-
dant results (either positive/negative discordance or
greater than twofold density difference above 400
parasites/μl) were resolved by an independent third
reading.We calculated parasite densities from the geo-
metric mean of the two closest counts of asexual para-
sites/200 white blood cells and the actual white blood
count or, if missing, 8000 cells/μl. We classified chil-
dren negative for P falciparum on microscopy and with
a positive rapid diagnostic test as “recent malaria”
because of the persistence of detectable HRP-2 for up
to one month after clearance of parasites.3
Blood for culture was inoculated into a BactALERT
Paediatric-fan bottle (bioMérieux, France) and incu-
bated in the BacT/ALERT 3D automated microbial
detection system. We used standard methods to
identify cultures that flagged positive. We determined
antimicrobial resistance patterns by disc diffusion and
E-test by using the interpretive criteria of the Clinical
Laboratory Standards Institute.20 We considered cul-
tures positive for non-cryptococcal yeasts, coagulase
negative Staphylococcus, Micrococcus, Corynebacterium,
Bacillus sp, or viridans group Streptococci to be contami-
nants and classified them as “negative culture” unless a
pathogenic organismwas also isolated.We considered
the following as indications for lumbar puncture,
regardless of malaria test result: history of multiple or
partial seizures, history of seizures in children aged
under 6months or over 6 years, confusion or reduction
in conscious level, bulging fontanelle, or neck stiffness.
We examined cerebrospinal fluid by microscopy and
cultured it. Bacterial identifications were indepen-
dently confirmed for Salmonella (Queensland Health
Forensic and Scientific Services, Brisbane, Australia),
Strep pneumoniae, or Haemophilus influenzae b isolates
(Netspear, Kilifi, Kenya). The laboratory participated
in a bacteriology external quality assurance pro-
gramme coordinated by a reference laboratory in
Moshi, Tanzania, which participates successfully in
external quality assurance programmes of the College
of American Pathologists and is monitored regularly
by theUSNational Institutes of Health and its contrac-
tors.
Data management and analysis
We used the Cardiff Teleform system (Cardiff, Vista,
CA, USA) to scan data into a Microsoft Access data-
base and analysed them in Stata-10. We calculated
nutritional z scores from NCHS/WHO reference
data in Epi-6 (CDC, Atlanta, USA). We used the χ2
test to compare proportions.
Table 1 shows the WHO criteria for antimicrobial
treatment used in the analysis; these are consistentwith
the pocket book version of the guideline produced in
2005.821 The guideline has been interpreted to apply
irrespective of P falciparum parasitaemia; this is consis-
tent with a previous study and justified by the finding
that P falciparum parasitaemia is common in asympto-
matic children.9 15 22 23 We used logistic regression
models to determine bivariable and multivariable
All admissions 1 June 2006 to 31 May 2007
(n=6470, 446 (6.9%) died)
Eligible and enrolled (n=3708)
Included in analysis (n=3639, 184 (5.1%) died)
Admitted out of study hours
(n=2136, 187 (8.8%) died)
Eligible but refused consent
(n=58, 4 (7%) died)
Not eligible or screening
data incomplete
(n=568, 69 (12.1%) died)
Admitted in study hours
(n=4334, 259 (6.0%) died)
Excluded owing to missing data
(n=69, 2 (3%) died)
Fig 1 | Admissions, deaths, inclusions, and exclusions during
study. 2383/3639 (65.5%) had an axillary temperature ≥37.5
on admission, 1234/3639 (33.9%) were afebrile with a
history of fever, and 22/3639 (0.6%) gave a history of fever
with no temperature recorded
Table 2 | Sensitivity and specificity of WHO “guidelines for care at first-referral level” criteria for antimicrobial treatment in identifying children with invasive
bacterial disease (IBD) by rapid diagnostic test (RDT) and blood slide results
Total cases (No;
% died) No (%) with IBD Sensitivity—% (95% CI) Specificity—% (95% CI) PPV (%) NPV (%) NNT*
% fatal cases with IBD
treated†
RDT and slide negative‡ 943 (56; 5.9) 143 (15.2) 72.7 (69.9 to 75.6) 47.3 (44.1 to 50.4) 19.8 90.6 5.1 88.9
RDT positive, slide
negative§
501 (33; 6.6) 98 (19.6) 67.3 (63.2 to 71.5) 49.9 (45.5 to 54.3) 24.6 86.3 4.1 83.3
Slide positive <5000/μl 405 (19; 4.7) 33 (8.1) 60.6 (55.9 to 65.4) 51.9 (47.0 to 56.8) 10.1 93.7 10.1 80.0
Slide positive 5000-50
000/μl
917 (33; 3.6) 31 (3.4) 67.7 (64.7 to 70.8) 55.9 (52.7 to 59.1) 5.1 98.0 19.6 66.7
Slide positive >50 000/μl 873 (43; 4.9) 36 (4.1) 52.8 (49.5 to 56.1) 51.6 (48.3 to 54.9) 4.5 96.2 22.3 60.0
NPV=negative predictive value; PPV=positive predictive value.
*Number needed to treat presumptively with antimicrobials to correctly treat one child with IBD.
†Proportion of all IBD associated fatalities with “guidelines for care at first-referral level” indication for antimicrobial treatment.
‡56 children were RDT negative and blood slide positive and are included in slide positive data (sensitivity of RDT compared with slide reading was 97.4%).
§Assumed to indicate recent infection with P falciparum.
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associations of invasive bacterial disease with WHO
criteria, HIV infection, fever, severe anaemia, hypo-
glycaemia, prostration, raised blood lactate, and recent
or current malaria.
RESULTS
During the one year of the study (June 2006 to May
2007) 6470 children were admitted; 4334 (67%) were
screened for inclusion; 3708 of these were eligible and
enrolled, of whom 3639 had sufficient data for analysis
(fig 1). The median age of children in the study was
1.6 years; 1054 (29.0%) were aged 2-11 months, 2273
(62.5%) were aged 12-59 months, and 312 (8.6%) were
aged 5-13 years.
Figure 2 summarises the prevalence of andmortality
associated with invasive bacterial disease, P falciparum
byblood slide, andHIV. Invasive bacterial diseasewas
identified in 341 (9.4%) of 3639 cases and in 58 (32%) of
184 deaths. Non-typhi Salmonella was the most fre-
quently isolated bacterial pathogen, accounting for 52
(52%) of 100 organisms in slide positive children and
108 (45%) of 241 in slide negative children. Mortality
among children with invasive bacterial disease (58/
341, 17%)was significantly higher than that in children
without invasive bacterial disease (126/3298, 3.8%)
(P<0.001), and this was true regardless of the presence
of P falciparum parasitaemia. The median duration of
admission was one day for fatal admissions and three
days for non-fatal admissions.
Performance of WHO criteria to target antimicrobial
treatment
Overall, the sensitivity of the WHO criteria to detect
invasive bacterial disease was 67.4% (95% confidence
interval 65.9% to 69.0%), with a specificity of 51.5%
(49.9% to 53.1%). Sensitivity was higher among slide
negative children (70.5%, 68.2% to 72.9%) than among
slide positive children (60.0%, 58.0% to 62.1%), and
specificity was slightly higher among slide positive
children (53.5%, 51.4% to 55.6%) than among slide
negative children (48.1%, 45.6% to 50.7%). The sensi-
tivity of the WHO criteria declined with increasing P
falciparum parasite density (P<0.05, χ2 test for trend);
among children with more than 50 000 parasites/μl,
only 19/36 (53%, 50% to 56%) children with invasive
bacterial disease were correctly identified (table 2).
WHO criteria were significantly more sensitive in
identifying invasive bacterial disease associated fatal-
ities (82.8%, 77.3% to 88.2%) than non-fatal invasive
bacterial disease (64.3%, 62.7% to 65.9%), yet 10
(17%) of 58 deaths among children with invasive bac-
terial disease remained unidentified by WHO criteria
as needing antimicrobials.
Table 3 shows the prevalence of infecting organisms
by WHO criteria of syndromic diagnosis. More than
three quarters (96/120, 80%) of children with Gram
P falciparum
(n=2051, 76 (3.7%) died)
No P falciparum, IBD†, or HIV‡
(n=1132, 38 (3.4%) died)
IBD*
(n=218,
39 (18%) died)
HIV
(n=71, 6 (8%) died)
n=23, 6 (26%) died
n=4, 0 died
n=44, 6 (14%) died
n=96,
13 (14%)
died
Fig 2 | Numbers and deaths of children infected with P falciparum by blood slide, invasive
bacterial disease (IBD), or HIV. Areas in Venn diagram approximately to scale. *IBD consisted
of 336 children with a positive blood culture, of whom 20 also had a positive cerebrospinal
fluid (CSF) culture, and an additional five with a pathogenic organism isolated from CSF and a
negative or contaminated blood culture. †Blood cultures classified as negative included 251
(6.9%) from which contaminant organisms only were cultured. ‡Three negative HIV results
were based on Capillus testing only (negative predictive value 99.5%, detail not shown); all
other HIV results were based on at least two concordant test results
Table 3 | Number (%) of children with and without one of WHO indications for antimicrobial treatment by organism isolated
from blood or cerebrospinal fluid
Guidelines indication
Non-typhi
Salmonella
Haemophilus
influenzae b
Other Gram
negative*
Strep
pneumoniae
Other Gram
positive†
No organism
isolated Total
Meningo-encephalopathy 7 (3) 18 (7) 5 (2) 5 (2) 4 (2) 216 (85) 255
Malaria with shock 4 (5) 0 2 (2) 0 0 76 (93) 82
Very severe pneumonia 31 (8) 6 (2) 10 (3) 15 (4) 5 (3) 311 (82) 378
Severe pneumonia 13 (7) 5 (3) 2 (1) 9 (5) 1 (5) 171 (85) 201
Non-severe pneumonia 39 (5) 4 (1) 15 (2) 15 (2) 6 (1) 766 (91) 845
Septicaemia 1 (4) 0 1 (4) 1 (4) 0 25 (89) 28
Severe acute malnutrition 2 (5) 1 (3) 2 (5) 1 (3) 0 34 (85) 40
No WHO indication‡ 63 (3.5) 5 (0.3) 24 (1.3) 10 (0.6) 9 (0.5) 1699 (93.9) 1810
One child in whom Strep pneumoniae was isolated from cerebrospinal fluid and non-typhi Salmonella was isolated from blood was classified as
infected with Strep pneumoniae alone.
*Included 23 E coli and 11 Salmonella typhi.
†Included 17 Staph aureus.
‡225/1810 (12.4%) of children who did not meet an existing WHO indication for antimicrobial treatment had severe anaemia (haemoglobin <5 g/dl).
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positive or H influenzae infections presented with clin-
ical features thatmet one of theWHOcriteria, whereas
just over half (134/221, 61%) of children with non-H
influenzae Gram negative infections met one of these
criteria (P<0.001). Non-H influenzae Gram negative
infections accounted for more than three quarters
(151/198, 76%) of organisms isolated in children with
recent or current malaria but less than half (70/143,
49%) of organisms isolated from children who were
both slide negative and rapid diagnostic test negative
(P<0.001) (fig 3).
Risk factors for invasive bacterial disease
Weassessed clinical and laboratory features associated
with invasive bacterial disease by using bivariate odds
ratios and a multivariable logistic regression model
(table 4). After control for the presence of any WHO
criteria,HIV infection, and current or recentmalaria, a
significant association remained between invasive bac-
terial disease and axillary temperature above 38°C,
severe anaemia (haemoglobin <5 g/dl), and hypogly-
caemia (blood sugar <2.5 mmol/l) (table 4). Prostra-
tionwas also associatedwith increased odds of invasive
bacterial disease among children without current or
recent malaria (odds ratio 2.54, 95% confidence inter-
val 1.37 to 4.70, P=0.003).
Additions to WHO criteria to improve sensitivity
To evaluate potential candidates for addition to the
WHO criteria, we identified factors from those asso-
ciated with invasive bacterial disease (table 4). We
added HIV first on the assumption that this would be
incorporated if WHO guidelines included care of chil-
dren with HIV in the “Fever” chapter. The further cri-
teria of “severe anaemia (Hb <5 g/dl),” “prostration,”
and “current fever >38°C” increased the sensitivity of
the WHO criteria to 86.2% (85.1% to 87.3%), with a
specificity of 24.8% (23.4% to 26.2%). Table 5 shows
these results by malaria slide results.
In slide positive children, the prevalence of invasive
bacterial disease was 60/1035 (5.8%) if one of the
WHO criteria was present compared with 26/679
(3.8%) if none was present but the child had any of
severe anaemia, prostration, HIV infection, or “cur-
rent fever >38°C.” This contrasts with slide negative
children, amongwhom the prevalence of invasive bac-
terial disease was 170/794 (21.4%) if one of the WHO
criteria was present compared with 38/265 (14%) if
none was present but the child had any of severe anae-
mia, prostration, HIV infection, or current fever >38°
C. Hypoglycaemia, although strongly associated with
invasive bacterial disease, applied to only 22 children
with such disease; all but three of these already met
WHO criteria, and all but two of them met one of the
criteria classified as D in table 5.
Antimicrobial susceptibility
In children with invasive bacterial disease, the isolated
organism was susceptible in vitro to the WHO recom-
mended antibiotic in 33% to 100% of cases, with a
weighted mean of 99/211 (47%). Co-trimoxazole for
non-severe pneumonia and parenteral penicillin for
severe pneumonia were associated with the lowest in
vitro susceptibilities (32% and 33%) (table 6). Table 7
shows susceptibilities of common isolates to routinely
available antibiotics.
DISCUSSION
Our findings show that, in a typical district hospital
serving a population exposed to intense transmission
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Fig 3 | Proportion of organisms isolated from children with
invasive bacterial disease by P falciparum infection status.
RDT=rapid diagnostic test
Table 4 | Logistic regression model of factors associated with invasive bacterial disease in all
children in study
Factors Unadjusted odds ratio (95% CI) Adjusted odds ratio (95% CI)
WHO criteria 2.20 (1.74 to 2.79)** 1.67 (1.28 to 2.17)**
Meningo-encephalopathy 1.84 (1.28 to 2.64)**
Malaria with shock 0.59 (0.34 to 1.00)
Very severe pneumonia 2.16 (1.67 to 2.81)**
Severe pneumonia 1.85 (1.25 to 2.74)**
Non-severe pneumonia 0.98 (0.75 to 1.28)
Septicaemia 5.58 (3.92 to 7.96)**
Severe acute malnutrition 1.72 (0.72 to 4.13)
HIV positive 2.38 (1.54 to 3.68)** 1.47 (0.91 to 2.35)
Axillary temperature >38°C 1.34 (1.07 to 1.67)* 1.44 (1.13 to 1.84)**
Prostration† 1.42 (1.03 to 1.95)* 1.01 (0.65 to 1.55)
Shock 1.14 (0.69 to 1.88) 0.90 (0.50 to 1.60)
Haemoglobin <5 g/dl 1.43 (1.08 to 1.89)* 1.56 (1.13 to 2.14)**
Glucose <2.5 mmol/l 2.33 (1.44 to 3.75)** 2.46 (1.39 to 4.35)**
Lactate >5 mmol/l 1.46 (1.07 to 1.99)*
Slide positive 0.24 (0.19 to 0.30)**
RDT positive, slide negative‡ 2.90 (2.24 to 3.75)** 1.29 (0.95 to 1.75)
Slide positive <5000/μl 0.84 (0.58 to 1.23) 0.55 (0.36 to 0.84)**
Slide positive 5000-50 000/μl 0.27 (0.19 to 0.40)** 0.20 (0.13 to 0.31)**
Slide positive >50 000/μl 0.35 (0.24 to 0.50)** 0.24 (0.16 to 0.37)**
RDT=rapid diagnostic test.
*P<0.05.
**P<0.001.
†Inability to sit unsupported or, if age <8 months, inability to drink.
‡RDT positive and slide negative assumed to indicate recent infection with P falciparum.
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of P falciparum, WHO criteria for antimicrobial treat-
ment failed to identify almost a third of children who
had definite invasive bacterial disease. Among those
who were identified by WHO criteria, the isolated
organismwas not susceptible to the first recommended
antimicrobial drug in more than half the cases.
As expected, invasive bacterial disease was more
likely in slide negative children than in slide positive
children. In these co-infected children, however, inva-
sive bacterial disease was not confined to those with
low density infections that are often found incidentally
in African children; a third of the invasive bacterial
disease-P falciparum co-infections occurred in children
with high density infections that are highly unlikely to
be due to incidental parasitaemia.22 This finding is con-
sistent with those of Berkley et al, who have recently
quantified the association of high densitymalaria infec-
tion and bacterial disease.24 In addition, we found that
invasive bacterial disease was associated with high
mortality irrespective of P falciparum infection, high-
lighting the importance of considering invasive bacter-
ial disease in children admitted to hospital irrespective
of whether a malaria slide is positive. The failure of the
WHOcriteria to identifymany of these childrenwas to
a large extent due to the high prevalence of non-typhi
Salmonella infection and its association with severe
anaemia and other non-specific clinical features that
are not currently included in the WHO criteria.8 The
introduction of pneumococcal and Hib vaccines in
many African countries in the next one to two years
is likely to make these infections relatively more
important.
Our results are consistent with increasing evidence
thatmalaria is a risk factor for non-typhi Salmonella and
some other Gram negative infections.12 24 25 Reasons
for this are still unclear but may relate to increased vul-
nerability to non-typhi Salmonella infection associated
with haemolysis, as the association also applies in chil-
drenwith sickle cell disease and in animalswith experi-
mentally induced haemolysis.26 27 The association of
non-typhi Salmonella with “recent malaria” that we
and one previous study have observed suggests that
malaria may result in relatively prolonged increased
vulnerability to bacterial infection, especially by
enteric organisms.3
Validity and generalisability of findings
Although no study can automatically be generalised to
other settings, our findings are similar to those of Berk-
ley et al, who found that in an area of moderate P falci-
parum transmission the WHO criteria correctly
identified 66% of invasive bacterial disease in slide
positive children and 76% in slide negative children
(after the exclusion of “sick young infants,” a group at
high risk of invasive bacterial disease who are all
recommended for antimicrobial treatment by these
guidelines).9 These figures are only slightly higher
than our estimates; the difference may be due to a
higher proportion of non-typhi Salmonella infections
in our study.
The diagnostic performance of the WHO criteria is
likely to vary with local epidemiology, especially in
relation to bacterial disease and malaria, but the con-
sistency of our findings with several others in identify-
ing non-typhi Salmonella and other Gram negative
infections as leading causes of bacteraemia in African
children suggest that our findings are likely to apply
widely.10 14 28-33 In addition, the low level of anti-
microbial susceptibility that we found is also consistent
with others.10 32 34-36 The association between malaria
and bacterial disease identified in our study is consis-
tent with several other studies and was slightly weaker
than found byBerkley et al.18 Similarly, the association
of increased mortality with bacterial disease is similar
to that found in several other studies,18 37 although a
study in Malawi did not find an association between
mortality and bacterial disease among children with
severe malaria admitted to a paediatric intensive care
unit.11
Table 5 | Sensitivity, specificity, and predictive values of selected additions to WHO “guidelines for care at first-referral level” criteria for presumptive
treatment of invasive bacterial disease (IBD) by presence or absence of P falciparum parasitaemia
Sensitivity—%
(95% CI)
Specificity—%
(95% CI) PPV (%) NPV (%) NNT*
% fatal cases with
IBD treated†
Blood slide positive for P falciparum
A—guidelines criteria 60.0 (58.0 to 62.1) 53.5 (51.4 to 55.6) 5.8 96.6 17.3 69.2
B—A or HIV 62.0 (60.0 to 64.0) 52.5 (50.4 to 54.6) 5.9 96.7 17.1 69.2
C—B or severe anaemia 68.0 (66.1 to 70.0) 45.3 (43.2 to 47.4) 5.6 96.7 17.9 84.6
D—C or prostration 72.0 (70.1 to 73.9) 43.4 (41.4 to 45.5) 5.7 97.0 17.5 92.3
E—D or axillary temperature >38°C 86.0 (84.6 to 87.5) 22.3 (20.6 to 24.0) 5.0 97.1 19.9 92.3
Blood slide negative for P falciparum
A—guidelines criteria 70.5 (68.2 to 72.9) 48.1 (45.6 to 50.7) 21.4 89.1 4.7 86.7
B—A or HIV 71.4 (69.0 to 73.7) 46.6 (44.1 to 49.2) 21.1 89.0 4.7 86.7
C—B or severe anaemia 75.5 (73.3 to 77.7) 42.4 (39.9 to 44.9) 20.8 89.6 4.8 88.9
D—C or prostration 75.9 (73.7 to 78.1) 42.0 (39.4 to 44.5) 20.8 89.7 4.8 91.1
E—D or axillary temperature >38°C 86.3 (84.5 to 88.1) 29.3 (26.9 to 31.6) 19.6 91.4 5.1 93.3
NPV=negative predictive value; PPV=positive predictive value.
*Number needed to treat presumptively with antimicrobials to correctly treat one child with IBD.
†Proportion of all IBD associated fatalities identified for antimicrobial treatment.
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A limitation of our study was our inability to enrol
children at night; case fatality was higher in children
admitted outside study hours, probably because “out
of hours” admissions aremore severely ill and possibly
because initial clinical management is of lower quality
at these times.38 Mortality was also high in children
who were excluded from the study because of missing
data (often because they died soon after admission),
and our findings are thus likely to underestimate mor-
tality in childrenwhose need for antimicrobialswas not
recognised by WHO criteria. However, children who
die soon after admission probably present too late to
benefit from antimicrobial treatment.
WHO guidelines
We evaluated the WHOmanual “Management of the
child with severe infection or severe malnutrition:
guidelines for care at first-referral level,”8 as this is the
standardWHO guide for paediatric inpatient care and
has been adopted as policy by the ministries of health
of many resource poor countries. A WHO guideline
for treatment of malaria (2006) also exists; it proposes
a “low threshold” for the use of antimicrobials in chil-
dren with severe malaria to treat Salmonella infections
in particular.17 The existence of separate clinical guide-
lines for malaria and general paediatric care is an
unfortunate consequence of the vertical approach to
malaria. Possibly as a result of this, antimicrobial treat-
ment is not mentioned in the Tanzanian or Kenyan
national guidelines for the treatment of severemalaria.
Additional indications for antimicrobials in children
Among children in this study, the addition of “severe
anaemia” and “prostration” to current indications
resulted in a significant improvement in the detection
of invasive bacterial disease in both fatal and non-fatal
cases. This is consistent with several studies that have
shown an association between severe anaemia and
invasive bacterial disease.11 29 39 “Current fever”’ has
previously been associated with invasive bacterial
disease,40 and its inclusion as a criterion for anti-
microbials resulted in a gain in sensitivity, although
this was at the expense of a substantial drop in specifi-
city. However, even in children with malaria, applica-
tion of these more inclusive criteria resulted in fewer
than 20 children qualifying for presumptive anti-
microbial treatment to correctly identify one child
with invasive bacterial disease, a figure that compares
favourably with policies that recommend presumptive
treatment of non-severe malaria.17 Given the increase
in mortality associated with invasive bacterial disease,
this seems a reasonable proposition; however, a need
exists for a more formal economic evaluation that
includes such factors as the financial cost of newer
Table 7 | Proportion (%) of bacterial isolates susceptible in vitro to commonly available antimicrobials
Penicillin/amoxicillin Chloramphenicol Co-trimoxazole Gentamicin
Non-typhi Salmonella* 49/148 (33) 53/153 (35) 49/145 (34) 147/152 (97)†
Strep pneumoniae 51/51 (100) 41/48 (85) 22/45 (49) –
Haemophilus influenzae 12/38 (32) 16/38 (42) 2/28 (7) 22/23 (96)
E coli 2/21 (10) 5/18 (28) 1/20 (5) 9/20 (45)
Staph aureus 1/15 (7) 11/13 (85) 10/14 (71) 13/16 (81)
Susceptibility includes “full” or “intermediate” susceptibility and follows Clinical Laboratory Standards Institute (CLSI) guidelines with exception of
susceptibility of Salmonella isolates (noted below).20
*Salmonella isolates were multi-resistant (resistant to amoxicillin, chloramphenicol, and co-trimoxazole) in 85/141 (60.3%) cases.
†Salmonella susceptibilities to gentamicin are shown as actual in vitro results, although CLSI guidelines recommend that for clinical practice all
Salmonella should be reported as “not susceptible” owing to poor intracellular penetration of gentamicin.
Table 6 | Proportion (%) of bacterial isolates susceptible in vitro to recommended and other commonly available antimicrobials by WHO “guidelines for care
at first-referral level” criteria for antimicrobial treatment*
Amp/chlor Pen/chlor Chlor Pen/gent† Pen Amoxy Co-trimox Amp/gent† Ceftriaxone Pen/cipro Azithromycin
Meningo-
encephalopathy
22/34 (65)‡ 19/34 (56) 16/32 (50) 22/24 (92) 5/38 (13) 13/34 (38) 6/25 (24) 28/29 (97) 31/31 (100) 12/13 (92) 26/29 (90)
Malaria with shock 2/6 (33) 2/6 (33)‡ 2/6 (33) 4/5 (80) 0/6 (0) 2/6 (33) 3/5 (60) 4/5 (80) 5/6 (83) 5/5 (100) 3/8 (38)
Very severe pneumonia 32/62 (52) 31/63(49) 26/62 (42)‡ 54/60 (90) 16/65 (25) 26/62 (42) 17/58 (29) 55/60 (92) 60/61 (98) 53/53 (100) 38/55 (69)
Severe pneumonia 20/29 (69) 19/30 (63) 17/29 (59) 29/29 (100) 10/30 (33)‡ 18/29 (62) 9/26 (35) 29/29 (100) 30/30 (100) 23/23 (100) 27/35 (77)
Non-severe pneumonia 38/69 (55) 36/69 (52) 30/66 (46) 63/72 (88) 16/76 (21) 32/71 (45)‡ 21/66 (32) 63/72 (88) 71/72 (996) 67/67 (100) 57/86 (66)
Septicaemia 1/2 (50) 1/2 (50)‡ 1/2 (50) 3/3 (100) 1/3 (33) 1/2 (50) 1/2 (50) 3/3 (100) 2/2 (100) 3/3 (100) 4/5 (75)
Severe acute
malnutrition
5/6 (83) 5/6 (83) 5/6 (83) 5/5 (100) 1/6 (17) 4/6 (67) 3/5 (60) 6/6 (100)‡ 6/6 (100) 5/5 (100) 3/5 (60)
Amoxy=amoxicillin; amp=ampicillin; chlor=chloramphenicol; co-trimox=co-trimoxazole; cipro=ciprofloxacin; gent=gentamicin; pen=penicillin.
*Susceptibility includes “full” or “intermediate” susceptibility and follows Clinical Laboratory Standards Institute (CLSI) guidelines with exception of susceptibility of Salmonella isolates
(noted below)20; not all isolates were tested for all antibiotics.
†Salmonella susceptibilities to gentamicin are shown as actual in vitro results, although CLSI guidelines recommend that for clinical practice all Salmonella should be reported as “not
susceptible” owing to poor intracellular penetration of gentamicin.
‡First recommendation treatment.
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antimicrobials and the selection of resistance that may
result from their wider use.
For routine care, the high mortality associated with
invasive bacterial disease, the low sensitivity of a single
blood culture,41 42 the poor quality of routine slide
results, and the apparently strong bias of hospital clin-
icians towards the diagnosis of malaria all suggest that
inclusive rather than restrictive indications for pre-
sumptive antimicrobial treatment are needed to ensure
more effective treatment for children admitted to hos-
pitals in resource poor settings.6 43 44
Choice of antimicrobials
Our results, which are consistent with those of other
studies, show that commonly used antimicrobials
often lack activity against the Gram negative organ-
isms that are often themost common cause of bacterial
infection in African children.10 32 34-36 In our study, two
thirds of the organisms identified in children who met
theWHO criteria for severe pneumonia were resistant
to penicillin (the first recommended antimicrobial) and
more than a third were resistant to chloramphenicol or
ampicillin (whichmight be used as an alternative). Our
in vitro estimate of susceptibility to gentamicin is likely
to overestimate its in vivo efficacy as, although some
extracellular effect against salmonellas can be
expected, salmonella is a largely intracellular organism
and the limited penetration of gentamicin is likely to
limit its effect.45 46 As a consequence, gentamicin is not
usually recommended for treatment of invasive
salmonellosis.20
The choice of antimicrobials in resource poor set-
tings is obviously constrained by cost and availability.
However, as recently highlighted by Graham and
English,47 the high incidence and fatality of non-typhi
Salmonella bacteraemia in Africa, which is often resis-
tant to commonly used antimicrobials, constitutes a
serious and neglected public health challenge. Better
evidence to guide antimicrobial choices is needed,
but current evidence suggests that in malaria endemic
areas of Africa ciprofloxacin (not usually available par-
enterally) plus penicillin or ceftriaxone alone are the
leading candidates for first choice antimicrobials in
severely ill children.
Clinical trials of antibiotic indications in sick children
Our results raise questions that ideally should be
informed by the results of a randomised clinical trial
of clinical indications for the use of antibiotics. How-
ever, such a trial would need to be large. According to
the data from our study and an assumption that anti-
microbials in children with severe malarial anaemia
and no WHO indication for antimicrobials would
reduce their mortality by 50% (although a much smal-
ler reduction would still be worthwhile), 2670 children
would need to be randomised from more than 17 000
children with severe malaria. In addition, ethical con-
cerns could exist about randomising severely anaemic
children to a “no antimicrobial” arm given the strength
of current evidence.11 29 39 WHO and others need to
reach a consensus on this question; if a clinical trial is
feasible and ethical, it should be set up with urgency. If
not, existing evidence should be used to help tomodify
current guidelines for the treatment of children with
invasive bacterial disease in malaria endemic areas.
Conclusions
The WHO criteria for presumptive antimicrobial
treatment have poor sensitivity in children living in
this area endemic for P falciparum in Africa, and the
guidelines should be re-examined. This study shows
that simple and available clinical criteria may signifi-
cantly increase detection of invasive bacterial disease
in severe and fatal illness in African children. Cur-
rently recommended antimicrobials often lack activity
against common bacterial infections in Africa, and
more effective diagnosis and treatment of bacterial dis-
ease in resource poor settings are urgently needed.
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